Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells

Cited by (189)

Items 101–189 of 189

1. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
   Cristiano Chaves, RAFAEL GUIMARÃES DOS SANTOS, Serdar Murat Dursun, Massimo Tusconi, Mauro Giovanni Carta, Elisa Macedo Brietzke, Jaime E. C. Hallak · 2024 · Frontiers in Psychiatry
2. Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease
   Albert Katchborian Neto, Mário F. C. Santos, Diego Fernandes Vilas Boas, Elda Gonçalves-Santos, Márcia Paranho Veloso, Paula Carolina Pires Bueno, Ivo Santana Caldas, Marisi Gomes Soares, Danielle Ferreira Dias, Daniela Aparecida Chagas‐Paula · 2022 · Chemistry & Biodiversity
3. An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
   Naif A Arishi, Naif Althomali, Ibrahim Mohammed Dighriri, Mohammed Saad AlHarthi, Ghadeer B Alqurashi, Razan A. Musharraf, Aeshah Hamed Albuhayri, Marwah K Almalki, Shatha Alhassan Alnami, Zamzam O Mashraqi · 2023 · Cureus
4. Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum
   Geoffrey M. Bove, David J. Mokler · 2022 · Journal of Psychedelic Studies
5. Intestinal inflammation-associated hypersensitivity is attenuated in a DSS model of colitis in Sigma-1 knockout C57BL/6 mice
   Sergio López‐Estévez, Georgia Gris, Beatriz de la Puente, Alicia Carceller, Vicente Martı́nez · 2021 · Biomedicine & Pharmacotherapy
6. Ayahuasca reverses ischemic stroke-induced neuroinflammation and oxidative stress
   Larissa da Silva Joaquim, Lara Rodrigues da Rosa, Yasmin Ribeiro Strickert, Richard Simon Machado, Everton Lanzzarin, Gabriela Bernardes, Suelen de Souza Ramos, Linério Ribeiro de Novais Júnior, Beatriz Steiner, Brenno Farias et al. · 2025 · Behavioural Brain Research
7. Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression
   Daniel do Nascimento Sousa, Monique de Abreu Azevedo, Maria Lucília dos Santos, Tatiana Karla dos Santos Borges, Daniela Mara de Oliveira, Eloísa Dutra Caldas · 2025 · Metabolic Brain Disease
8. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
   Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J Cooper, John Gordon, Catherine Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews et al. · 2025 · British Journal of Pharmacology
9. Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice
   Martin L Williams, Karen I Hitchcock, Angus H. Miller, Simon A. Beck · 2025 · General Hospital Psychiatry
10. Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating
    José Alexandre Salerno, Thayana Torquato, Jairo Ramos Temerozo, Livia Goto‐Silva, Karina Karmirian, Mayara Abud Mendes, Carolina Q. Sacramento, Natalia Fintelman Rodrigues, Letícia R. Q. Souza, Isis Moraes Ornelas et al. · 2021 · PeerJ
11. Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design
    Pablo Miranda, Analía Castro, Paola Díaz, Lucía Minini, Florencia Ferraro, Erika Paulsen, Ricardo Faccio, Helena Pardo · 2024 · Polymers
12. Narrating the psychoneuroimmunomodulatory properties of serotonin 5-HT2A receptor psychedelics from a transdiagnostic perspective
    Guillaume Thuery, Christopher Sheridan, Patricia Iusan, Gurjot Brar, Kathryn Ledden, Aoife Freyne, John Richard Kelly, Andrew Harkin · 2025 · Acta Neuropsychiatrica
13. Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro
    José Alexandre Salerno, Stevens Kastrup Rehen · 2024 · iScience
14. Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis
    Noah D. Gold, Austin J. Mallard, Jacob C. Hermann, Richard J. Zeifman, Broc A. Pagni, Michael P. Bogenschutz, Stephen Ross · 2023 · Journal of Palliative Medicine
15. Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. The Switch Study Investigators.
    Martin G. Myers, C B Toal · 1995 · PubMed
16. Serotonin, immune function, and psychedelics as potent anti-inflammatories
    Charles David Nichols, Timothy P. Foster · 2025 · International review of neurobiology
17. Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
    Zoe Plummer, Josh Allen, Justin Brand, Leah M. Mayo, Sandy R. Shultz, Brian R. Christie · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
18. CircRNA-Based Therapeutics: a New Frontier in Neuroinflammation Treatment
    Thikra Majid Muhammed, Saade Abdalkareem Jasim, Subasini Uthirapathy, Viralkumar B. Mandaliya, Suhas Ballal, Rishiv Kalia, Renu Arya, Prashant Nakash, Yasser Fakri Mustafa, Jawad Kadhim Ahmed · 2025 · Molecular Neurobiology
19. Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein
    Patrícia Cavalcanti-Ribeiro, Lara Carvalho Araújo Melo De Souza, Vagner Deuel de Oliveira Tavares, Raíssa Nóbrega de Almeida, Nicole Bezerra de Medeiros Lima, Kaike Thiê da Costa Gonçalves, Eduardo Igor Torquato Cardoso Lopes, Raynara Bolcont, Aldielyson Jorge Cavalcante de Brito, Marcelo Falchi-Carvalho et al. · 2025 · Journal of Affective Disorders
20. Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
    Rabeet Tariq · 2022 · Current Clinical Pharmacology
21. 1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
    Sylvana Vilca-Melendez, Malin Vedøy Uthaug, Julian Leether Griffin · 2021 · Frontiers in Psychiatry
22. Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility
    José Alexandre Salerno, Thayana Torquato, Jairo Ramos Temerozo, Livia Goto‐Silva, Mayara Abud Mendes, Carolina Q. Sacramento, Natalia Fintelman Rodrigues, Gabriela Vitória, Leticia Souza, Isis Moraes Ornelas et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
23. Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
    Natasha Leigh Mason, Attila Szabó, Kim P. C. Kuypers, Pablo Mallaroni, Rafael de la Torre, Johannes T. Reckweg, Desmond H. Y. Tse, Nadia R. P. W. Hutten, Amanda Feilding, Johannes Gerardus Ramaekers · 2022 · medRxiv
24. Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia
    Jacopo Sapienza, Marco Spangaro, Stefano Comai, Michel Sabé, Joseph T. La Torre, Matteo Buonarroti, Roberto Cavallaro, Marta Bosia · 2025 · International Journal of Molecular Sciences
25. The immunomodulatory effects of psychedelics in Alzheimer’s disease-related dementia
    Alireza Mohammad Hosseini, Hossein Khaleghzadeh‐Ahangar, Atena Rahimi · 2024 · Neuroscience
26. Making Sense of Psychedelics in the CNS
    Blake A. Fordyce, Bryan L. Roth · 2024 · The International Journal of Neuropsychopharmacology
27. Corrigendum: A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus
    Rafael Vitor Lima da Cruz, Thiago C. Moulin, Lyvia Lintzmaier Petiz, Richardson Naves Leão · 2019 · Frontiers in Molecular Neuroscience
28. An encounter with death: a comparative thematic and content analysis of naturalistic DMT experiences and the near-death experience
    Pascal Michael, David P. Luke, Oliver C. Robinson · 2025 · Frontiers in Psychology
29. From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs
    Victor Pablo Acero, Taylor A. Flatt, Peter M. Gooch, Skylar J. Gaughan, Adam W. Levin, Alan K. Davis · 2025 · Expert Review of Clinical Pharmacology
30. Clinical pharmacology of ayahuasca: potential applications and future considerations
    Lorena Terene Lopes Guerra, Isabella Caroline da Silva Dias, Jaime E. C. Hallak, RAFAEL GUIMARÃES DOS SANTOS · 2025 · Expert Review of Clinical Pharmacology
31. Targeting Neuroinflammation in Depression: The Integrative Role of Sigma‐1 Receptor Modulation
    Jing‐Ya Wang, De‐Yi Yang, Yunfeng Li, Peng Ren · 2026 · Journal of Neurochemistry
32. The protective effect of DMT against neurodegeneration
    Ede Frecska, Attila Istvan Kovacs, Attila Szabó · 2025 · International review of neurobiology
33. “Immunohistochemical analysis of Sigma-1 receptor (σ-1R) expression in human pineal gland in relation to different causes of death”
    Cristina Mondello, Antonio Girolamo Micali, Gennaro Baldino, Luigi Cardia, Angela Alibrandi, Alessio Asmundo, Daniela Sapienza, Domenico Puzzolo, Elvira Ventura Spagnolo · 2024 · Legal Medicine
34. Ethnobotanical Significance, Phytopharmacology, and Toxicological Profile of Limonia acidissima L. (Rutaceae): A Review
    Satyajit Mohanty, Ashok Kumar Pattnaik · 2024 · Combinatorial Chemistry & High Throughput Screening
35. Pharmacology and Structure-Activity Relationship of Natural Products With Psychoactive Effects From Salvia divinorum, Mitragyna speciosa, and Ayahuasca
    S.M. Phipps, Oliver Grundmann · 2017 · Studies in natural products chemistry
36. Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
    Michael Davidson, Gabriela Dumitriţa Stanciu, Jonathan Rabinowitz, Ilinca Untu, Romeo Dobrin, Bogdan-Ionel Tamba · 2025 · Dialogues in Clinical Neuroscience
37. Immunomodulatory and anti-inflammatory effects of fluvoxamine during the intestinal phase of Trichinella spiralis infection in mice
    WESAM M. A. ELGENDY, Ahmad Ali Othman, Nema Ali Soliman, Nivin Naeem Mohammad Baiomy, Dina Magdy El-Guindy, Dina I. Elgendy · 2025 · Parasitology Research
38. Fluvoxamine attenuates inflammation in experimental sepsis via novel non-canonical pathways
    Luís Henrique Angenendt da Costa, Isis Paiva Trajano, Wanderson S. Santos, Katiuscia Martins de Araujo, Luiz G.S. Branco · 2025 · Inflammopharmacology
39. Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease
    Javier Calleja‐Conde, Víctor Echeverry‐Alzate, Marina Sanz-SanCristóbal, Sandra Alonso‐Gil, Elena Giné, Kora‐Mareen Bühler, Jose A. López-Moreno, Ana Perez-Castillo, Jose Angel Morales-Garcia · 2026 · Experimental Neurology
40. Mimosa tenuiflora (Willd.) Poir e Anadenanthera colubrina como alternativas no tratamento da adicção às drogas
    Patrícia Caroline Machado de Sousa, Italo Nunes Arrais de Sousa, Lucas Luan Lima Leite, André Luiz Ozório Oliveira, Karina Aparecida da Silva Souza, Jôslanne dos Santos Soares, Melquisedeque da Rocha Viana, Maurício Pires de Moura do Amaral · 2021 · Research Society and Development
41. Unique biological and physiological properties of endogenous N, N-dimethyltryptamine from the perspective of functioning of the nervous system
    Jakub Schimmelpfennig, Kamila Jankowiak-Siuda · 2023 · Neuropsychiatria i Neuropsychologia
42. Genetic and Pharmacological Blockade of Sigma-1 Receptors Attenuates Inflammation-Associated Hypersensitivity during Acute Colitis in CD1 Mice
    Sergio López‐Estévez, Mònica Aguilera, Georgia Gris, Beatriz de la Puente, Alicia Carceller, Vicente Martı́nez · 2023 · Biomedicines
43. The Potential Use of Dimethyltryptamine against Ischemia-reperfusion Injury of the Brain
    Kovacs Attila, Anna Mathe, Ede Frecska · 2024 · Journal of Neuroscience and Neurological Disorders
44. Targeting the sigma-1 receptor with pridopidine induces functional neurorestoration in spinal cord ischemia-reperfusion injury
    Eman M. Sweed, Suzan A Khodir, Shaimaa Mohamed Motawea, Hala El-Haroun, Basma Abdelnaby Mostafa, Mona Sabry Elkholy, Mohammud Ahmud Salim, Doaa Z. M. Shebl · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
45. All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegener-ative diseases through mitochondrial activation
    Milena Batalla · 2023 · Science Reviews Biology
46. Plantas sagradas amerindias, persecución y renacimiento
    Luis Eduardo Luna Porras · 2018 · Cultura y Droga
47. Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?
    E. Amit Romach, M. Nachliely, Olivia M. Moran, Michèle Brami, I. Lamensdorf · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
48. The IRE1-XBP1 Branch of the Unfolded Protein Response Underpins Cytokine Induction and Viral Replication in SARS-CoV-2 Infection
    José Javier Fernández Rodríguez · 2023
49. Cation-π interaction of N,N-Dimethyltryptamine in hydrochloric acid solution characteristic to gastric acid
    Andrej Vidak, Iva Movre Šapić, Vladimir Dananić · 2015 · Integrative Molecular Medicine
50. Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review
    Hunter W. Korsmo · 2024 · Livers
51. Exploring the importance of bodyset for the psychedelic experience and beyond
    Malin Vedøy Uthaug, Giancarlo Allocca, Martha Nari Havenith, Attila Szabó, Fernando E. Rosas, Johannes Gerardus Ramaekers · 2025 · Journal of Psychedelic Studies
52. Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
    Sheida Shadani, Erika Greaves, Zane Bruce Andrews, Claire J. Foldi · 2026 · Psychedelics.
53. Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine
    Burton Jared Tabaac, Kenneth Shinozuka, Anne Weisman, Shiven Chaudhry, Mathieu Seynaeve, Owen S. Muir · 2026 · American Journal of Therapeutics
54. Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine
    Alan C. Courtes, Blake Myers, Noah Daly, Greg Jones, Jair C. Soares, Carlos A. Zarate, Rodrigo Machado‐Vieira · 2026 · General Hospital Psychiatry
55. Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review
    Caio Cesar de Paula, Anna Beatriz Vicentini, Lorena Terene Lopes Guerra, José Carlos Bouso, Jaime E. C. Hallak, RAFAEL GUIMARÃES DOS SANTOS · 2026 · Journal of Psychopharmacology
56. Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action
    Jordana Kazdan, Karim Shiraz Ladha, M. Ishrat Husain · 2026 · Pharmacology Research & Perspectives
57. Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland
    John Richard Kelly, Christopher Sheridan, Patricia Iusan, Lisa Coakley, Lisa Burke, Christine Brennan, Annie Annie MacDonald, Jo‐Hanna Ivers, Dominic Trépel, Garrath Tormey et al. · 2026 · The International Journal of Neuropsychopharmacology
58. The role of nutrition in psychedelics clinical trials: Key considerations and recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
    Agnieszka Mechlińska, Aleksander Kwaśny, Michał Pastuszak, Wiesław Jerzy Cubała · 2026 · Nutritional Psychiatry
59. A Systematic Literature Review of the Potential Therapeutic Effects of Ayahuasca Tea Prepared From the Use of Banisteriopsis Caapi and Psychotria Viridis
    Adriane Cordeiro Trevisani, João Pedro Cordeiro Trevisani, Moacir Haverroth, Ailton da Cruz Melo, Isabela Carvalho dos Santos, Lidiane Nunes Barbosa, Daniela Dib Gonçalves · 2020 · Journal of Agricultural Studies
60. Medical Use of Cannabinoids and Psychedelic Compounds
    Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi · 2023 · Springer eBooks
61. Osteoinductive accelerating potential of myxobacterial secondary metabolites
    Hamide Parhizkari, Fatemeh Mohammadipanah, Mahshid Hodjat · 2024 · The Microbe
62. Tryptamine based drugs
    Shaun L. Greene · 2025 · Comprehensive analytical chemistry
63. Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report
    David Wyndham Lawrence, Alex P. Di Battista, Michael G. Hutchison · 2025 · Psychoactives
64. Phenomenology and psychosomatics: a Jungian and post-Jungian approach
    Attila Szabó · 2016
65. Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine
    Jan M. Keppel Hesselink, Jan M. Keppel Hesselink · 2019 · International Journal of Psychotherapy Practice and Research
66. Peer Review #2 of "Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating (v0.1)"
    2021 · PeerJ
67. Peer Review #1 of "Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating (v0.1)"
    2021 · PeerJ
68. The pharmacological suppression of spreading depolarization in ischemic neuroprotection
    Írisz Szabó · 2020 · SZTE Repository of Dissertations (University of Szeged)
69. Alzheimer’s disease, dementia, aging, and COVID-19
    Elena L. Paley · 2023 · Elsevier eBooks
70. Medical Use of Cannabinoids and Psychedelic Compounds
    Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi · 2023 · Springer eBooks
71. On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
    Daniël Hoyer · 2024
72. Medical Use of Cannabinoids and Psychedelic Compounds
    Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi · 2024 · Springer eBooks
73. Inducing Effect of a Soil Myxobacterium Metabolite on Odontoblastic Differentiation of Dental Pulp Derived Stem Cells
    Hamide Parhizkari, Fatemeh Mohammadipanah, Maryam Pourhajibagher, Mahshid Hodjat · 2025 · Regenerative Engineering and Translational Medicine
74. Ayahuasca, Pain, and Inflammation: A Systematic Review of Preclinical Studies
    Bianca Villanova, Giordano Novak Rossi, Lorena Terene Lopes Guerra, José Carlos Bouso, Jaime E. C. Hallak, RAFAEL GUIMARÃES DOS SANTOS · 2025 · Psychoactives
75. Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)
    Sheida Shadani, Erika Greaves, Zane Bruce Andrews, Claire J. Foldi · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
76. Medicinal Mushrooms and Mental Disorders: How Mushrooms Affect Anxiety and Depression
    Anahita Tarki, Arman Hajikarim‐Hamedani, Setareh Rassa, Sepehr Khosravi · 2025 · Nutritional neurosciences
77. Potential molecular pathways and therapeutic implications of rapid-acting antidepressants on myelin biology: a scoping review
    Antonio Inserra, Colin J. Murray, Antonella Campanale, Jared VanderZwaag, Marie‐Ève Tremblay · 2026 · Frontiers in Neuroscience
78. Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats
    Paola Andrea Caro Aponte, Edison Huertas Montoya, Ítalo Odone Mazali, Alessandra Sussulini, Benedito Barraviera, Rui Seabra Ferreira, Luciana Politti Cartarozzi, Alexandre Leite Rodrigues de Oliveira · 2026 · Journal of Neurochemistry
79. Hallucinogenic Therapy in Alzheimer’s Disease targeting Mitochondria-Associated Membranes
    Fernando Minauro‐Sanmiguel, Héctor Vargas-Pérez · 2026 · Neuroscience
80. Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
    James Chmiel, Filip Rybakowski · 2026 · International Journal of Molecular Sciences
81. Psychedelics and microglia in aging: unraveling the secret dialogue behind healthy aging, mental health, and neuroinflammation
    Antonio Inserra, Jared VanderZwaag, Antonella Campanale, Colin J. Murray, Attila Jozsef Szabo · 2026 · Elsevier eBooks
82. Fabricated ancestrality: The Sonoran Desert toad, psychedelic globalization, and the ecological politics of 5-MeO-DMT
    Ana María Ortiz Bernal, C L Raison, A.M Vargas Prieto, A.K. Davis · 2026 · Psychedelics
83. Pretreatment with the psychedelic DOI mitigates LPS-induced hippocampal inflammation and behavioral impairments in mice
    Michael Fiorillo, Javier González-Maeso · 2026 · BMC Neuroscience
84. Psychedelics; an untapped therapeutic niche: a narrative review in the future of cancer pain management
    Maxine Min Chien Yap, Yasir Marwan Abdalla Omer, Yu Xuan Cheng, Wei Qi Chan, Satoshi Ogawa · 2026 · Medicine in Drug Discovery
85. Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects
    Zhen Xuen Brandon Low · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
86. La mort, un trip psychédélique ?
    Anna Carthaus · 2026 · Cerveau & Psycho
87. Classic psychedelics and autism spectrum disorder: preclinical evidence, mechanistic insights and unresolved challenges
    Fabrizio Ascone, Diletta Giangiacomo, Viviana Trezza · 2026 · Neuroscience & Biobehavioral Reviews
88. Potential Role of Psychedelics in the Treatment of Depressive Disorder
    Sheng‐Min Wang, Won-Myong Bahk · 2026 · Springer eBooks
89. Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics
    Anna Skovgaard Lerche, D.Parker Kelley, Michael E. Benros, Gerald Bernard Billac, Ellen Bradley, Boris Dov Heifets, Joshua D. Woolley, Kristen M. Nishimi, Aoife O’Donovan · 2026 · Brain Behavior and Immunity